Polyaspartic acid (PAA) ameliorates experimental gentamicin nephrotoxicity despite marked accumulation of gentamicin in the renal cortex. The experiments described here probe the extent of PAA's nephroprotective action when increasing doses of gentamicin, in excess of an established nephrotoxic dose (40 mg/kg of body weight per day), are administered. After 10 days, virtually complete nephroprotection was conferred by PAA coadministered to animals receiving three times the nephrotoxic dose (120 mg/kg/day) of gentamicin.
Polyaspartic acid (PAA) prevents experimental gentamicin nephrotoxicity despite marked accumulation of aminoglycoside in renal cortical tissue (3, 8, 9) . In addition to PAA, a number of other polyanionic compounds have been reported to confer nephroprotection (2, (4) (5) (6) (7) in aminoglycoside models, but PAA remains the most extensively studied to date. Clinically, it is well established that peak serum aminoglycoside concentrations correlate with bactericidal efficacy, while increased frequency of dosing correlates with nephrotoxicity. Theoretically, a full day's dose of aminoglycoside could be given with PAA to provide maximal antibacterial efficacy while minimizing nephrotoxicity. In patients with preexisting renal dysfunction, nephroprotection rendered by PAA might be particularly advantageous if it allows adequate peak aminoglycoside levels. It has been difficult to characterize PAA's pharmacodynamic and pharmacokinetic properties because no consistent formulation is currently available. The PAA compound used for most experimental studies represents a mixture of variable-length polymers composed of both D and L optical isomers. The following experiments were performed to examine the extent of nephroprotection conferred by PAA when gentamicin was given in multiples of known nephrotoxic doses for 10 days.
Acclimatized given one of the following treatments: diluent only, gentamicin at 80 mg/kg/day (G80), G120, G80 plus PAA, G120 plus PAA, and G160 plus PAA. Animals were treated for 3, 5, 7, and 10 days. At sacrifice, blood was obtained for determination of the blood urea nitrogen and serum creatinine levels by standard methods. One kidney from each animal was processed for light microscopy. The second kidney was weighed, homogenized in 1 N NaOH, digested at 80°C for 15 min, allowed to cool to room temperature, and then assayed for gentamicin with a polarized fluorescence immunoassay (Abbott TDX). The assay has a lower limit of sensitivity of 0.1 ,ug/ml. Recovery studies using known standards showed greater than 90% yield. The renal histopathologic techniques have been described previously (3) . One pathologist evaluated all renal sections in a masked fashion and reported the estimated percentage of necrotic and regenerating cortical tubular cells.
Statistical analysis was performed with the software program Abstat from Anderson-Bell, Parker, Co. The analysis of variance program, which tests for significant differences among the means of four-way unequal n groups of data, was used with Scheffes post hoc test with a significance level of 0.05. Diluent only 0. cant elevation in serum creatinine levels in the G120-treated animals compared with those in all PAA-exposed animals as well as controls. After 10 days, serum creatinine values for the groups treated with G80 plus PAA and G120 plus PAA did not differ from those for controls, while severe renal dysfunction was apparent in the groups treated with gentamicin alone.
Histologically, tubular epithelial cell necrosis and regeneration were absent after 10 days in the G80 plus PAA group and thus did not differ from the control group (Table 2) . Minimal tubular necrosis and regeneration were present in the G120 plus PAA group, although there was no impairment of renal function, as evidenced by the normal serum creatinine value for this group. Severe tubulointerstitial damage was present after 10 days in all groups treated with gentamicin alone. The G160 plus PAA group displayed a less abnormal tubular injury pattern than did the groups treated with gentamicin alone.
The renal gentamicin content in animals treated with gentamicin alone fell as the serum creatinine level rose, and tubular damage increased at days 7 and 10 (Table 3) . After 10 days, all PAA-exposed animals accumulated four times as much gentamicin in their renal parenchyma as the rats treated with gentamicin alone. Renal aminoglycoside accumulation correlated with preservation of histology and serum creatinine values in the groups treated with G80 plus PAA and G120 plus PAA. b Values are means + standard deviations for four rats. *, P < 0.05 versus all other groups, days 3 and 5. **, P < 0.0001 versus all other groups, day 7. ***, P < 0.0001 versus all other groups, day 10.
In this study, a dose range of gentamicin was probed to define the limits of PAA's nephroprotective effect in experimental aminoglycoside nephrotoxicity. In our laboratory, G40, given as two equal doses, produces renal dysfunction and tubular necrosis in 10 days (1) . PAA produces complete protection from this toxic insult (3). In the experiment described above, gentamicin doses of 80, 120, and 160 mg/kg/day, given as a single daily dose, were coadministered with PAA for 3, 5, 7, and 10 days. When the established daily nephrotoxic dose of gentamicin (40 mg/kg/day) was doubled and tripled, PAA provided nephroprotection after 7 and 10 days as evidenced by normal creatinine values and minimal or absent tubular necrosis and regeneration, in contrast to those of animals treated with gentamicin alone. Although renal dysfunction occurred in animals receiving G160 plus PAA, it was significantly less severe than that in animals receiving lower gentamicin loads (80 and 120 mg/kg/day) without PAA (P < 0.05). These findings reinforce the potential clinical benefit of PAA with regard to nephrotoxicity prevention in the setting of high aminoglycoside loads. Combining large gentamicin doses and concomitant PAA administration with less frequent dosing schedules would, in theory, maximize antibacterial efficacy while minimizing nephrotoxicity.
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